


Product Name : LOXO-101
Cat. No. : PC-43265
CAS No. : 1223403-58-4
Molecular Formula : C₂₁H₂₂F₂N₆O₂
Molecular Weight : 428.4352
Target : Trk Receptor
Solubility : DMSO: ≥ 4.6 mg/mL



Biological Activity

LOXO-101 (ARRY-470, Larotrectinib) is potent, selective pan-**TRK** inhibitor with cellular IC₅₀ of 2-20 nM against TRKA, TRKB, and TRKC kinases.

LOXO-101 demonstrates excellent selectivity against a panel of 226 non-TRK kinases with one exception (TNK2 IC₅₀=576 nM).

LOXO-101 inhibits fusion oncoprotein and cellular proliferation in TRK-fusion-bearing human-derived cancer cell lines.

LOXO-101 markedly attenuates bone cancer pain and significantly blocks the ectopic sprouting of sensory nerve fibers and the formation of neuroma-like structures in the tumor bearing bone.

LOXO-101 inhibits tumor growth in vivo in TRK fusion-positive cancer models.

References

Doebele RC, et al. *Cancer Discov.* 2015 Oct;5(10):1049-57.

Ghilardi JR, et al. *Mol Pain.* 2010 Dec 7;6:87.

Vaishnavi A, et al. *Nat Med.* 2013 Nov;19(11):1469-1472.

Drilon A, et al. *N Engl J Med.* 2018 Feb 22;378(8):731-739.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com